-
Perioperative Intravesical Therapy to Prevent Tumor Implantation?
- MMC
- Epirubicin - used in europe
A single dose administered within 6 hours lessens recurrence rates, whereas a dose 24 hours later does not.
BCG can never be safely administered immediately after TUR because the risk of bacterial sepsis and death is high
-
Successful Perioperative Administration of Intravesical Chemotherapy?
-
MOA of immunotherapy?
- Induced expression of cytokines in the urine and bladder wall and by an influx of granulocytes, mononuclear, and dendritic cells.
- The initial step appears to be direct binding to fibronectin within the bladder wall, subsequently leading to direct stimulation of cell-based immunologic response and an antiangiogenic state.
- The observed pattern of cytokine induction with preferential upregulation of interferon-γ, IL-2, and IL-12 reflects induction of a T-helper type-1 (Th1) response.
-
Indication of BCG?
- In patients with intermediate- and high-risk tumours, intravesical BCG after TURB reduces the risk of tumour recurrence.
- It is more effective than TURB alone or TURB +intravesical chemotherapy.
- Three-year maintenance is more effective than one year to prevent recurrence in patients with high-risk tumours, but not in patients with intermediate-risk tumours.
-
Method of BCG therapy?
- Treatments begun 2 to 4 weeks after tumor resection, allowing time for reepithelialization, which minimizes the potential for intravasation of live bacteria.
- For the same reason, a urinalysis is usually performed immediately before instillation to further ensure a diminished probability of systemic uptake of BCG.
- In the event of a traumatic catheterization, the treatment should be delayed for several days to 1 week, depending on the extent of injury.
- After instillation, the patient should retain the solution for at least 2 hours. Some clinicians have advocated the patient turn from side to side to bathe the entire urothelium, but there is no scientific support for this practice.
- Fluid, diuretic, and caffeine restriction before instillation is essential to limit dilution of the agent with urine and to facilitate retention of the agent for 2 hours
-
BCG schedule? *
Induction phase: weekly for six weeks, followed by check cystoscopy ad cytology.
Maintenance phase: on 3,6,12,18,24,30,36 months for 3 weeks on each phase.
-
Role of Quinolones in BCG therapy?
Quinolones may affect the viability of BCG and should be avoided if possible during the course of BCG treatments
-
Contraindications to Bacillus Calmette-Guérin (BCG) Therapy?
- Absolute Contraindications:
- Immunosuppressed and immunocompromised patients
- Immediately after transurethral resection on the basis of the risk of intravasation and septic death
- Personal history of BCG sepsis
- Gross hematuria (intravasation risk)
- Traumatic catheterization (intravasation risk)
- Total incontinence (patient will not retain agent)
- Relative Contraindications
- Urinary tract infection (intravasation risk)
- Liver disease (precludes treatment with isoniazid if sepsis occurs)
- Personal history of tuberculosis (risk theorized but unknown)
- Poor overall performance status
- Advanced age
- No or Insufficient Data on Potential Need for Contraindications
- Patients with prosthetic materials
- Ureteral reflux
- Anti–tumor necrosis factor medications (theoretically predispose to BCG sepsis)
-
Cleveland Clinic Approach to Management of Bacillus Calmette-Guérin (BCG) Toxicity
-
Effect of combination of BCG and interferon?
Potential superiority of the combination or the possibility of decreasing the dosage of BCG, which may reduce side effects.
-
Classification of persistent disease after BCG therapy?
BCG refractory - nonimproving or worsening disease despite BCG
BCG resistant - recurrence or persistence of lesser degree, stage, or grade after an initial course, which then resolves with further BCG
BCG relapsing - recurrence after initial resolution with BCG
BCG-refractory patients in particular are an especially high-risk group and should be strongly considered for immediate cystectomy if young and in generally good health.
Declaring failure may take up to 6 months because the response rate for patients with high-grade bladder cancer treated with BCG rose from 57% to 80% between 3 and 6 months after therapy
-
Treatment of carcinoma in situ?
- CIS cannot be cured by an endoscopic procedure alone.
- Compared to intravesical chemotherapy, BCG treatment of CIS increases the complete response rate, the overall percentage of patients who remain disease free, and reduces the risk of tumour progression.
|
|